行情

ZGNX

ZGNX

Zogenix
NASDAQ

实时行情|Nasdaq Last Sale

18.20
+0.28
+1.56%
盘后: 18.20 0 0.00% 16:19 06/11 EDT
开盘
17.83
昨收
17.92
最高
18.31
最低
17.68
成交量
61.67万
成交额
--
52周最高
32.42
52周最低
16.73
市值
10.16亿
市盈率(TTM)
-4.2301
分时
5日
1月
3月
1年
5年
内幕消息趋势:购买时延长了Zogenix内幕消息90天购买趋势
MT Newswires · 05/12 20:03
雷蒙德·詹姆斯(Raymond James)维持对Zogenix(ZGNX)的持有评级
Raymond James analyst Danielle Brill maintained a Hold rating on Zogenix (ZGNX) yesterday. The company's shares closed last Thursday at $17.53, close to
SmarterAnalyst · 05/07 11:59
每日生物技术脉搏:Chemocentryx,NKarta-CRISPR在细胞治疗合作,Orphazyme的临床试验挫折,2次IPO中的分歧判决
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 05/07 11:40
Northland Securities认为Zogenix的股票即将回升
In a report released today, Carl Byrnes from Northland Securities reiterated a Buy rating on Zogenix (ZGNX), with a price target of $65.00. The company's
SmarterAnalyst · 05/07 10:47
Zogenix(ZGNX)收到瑞穗证券的买入
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Zogenix (ZGNX), with a price target of $55.00. The company's
SmarterAnalyst · 05/07 08:15
8-K:ZOGENIX,INC。
(EDGAR Online via COMTEX) -- 5/6/20210001375151FALSE00013751512021-05-062021-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/06 22:29
回顾:Zogenix Q1收益
Shares of Zogenix (NASDAQ:ZGNX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 85.19% year over year to ($1.00), which beat the estimate of ($1.02).
Benzinga · 05/06 21:23
Zogenix Q1 EPS $(1.00)胜过$(1.02)预估,销售额$ 1,370万击败$ 1,233万预估
Zogenix (NASDAQ:ZGNX) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.02) by 1.96 percent. This is a 85.19 percent decrease over losses of $(0.54) per share from the same
Benzinga · 05/06 20:40
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ZGNX最新的财务预测,通过ZGNX每股收益,每股净资产,每股现金流等数据分析Zogenix近期的经营情况,然后做出明智的投资选择。
分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ZGNX价格均价为48.70,最高价位65.00,最低价为23.00。
EPS
机构持股
总机构数: 255
机构持股: 7,157.56万
持股比例: 128.24%
总股本: 5,581.26万
类型机构数股数
增持
40
432.38万
建仓
20
290.09万
减持
58
405.26万
平仓
21
106.62万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.29%
制药与医学研究
-0.72%
高管信息
Non-Executive Chairman/Independent Director
Cam Garner
President/Chief Executive Officer/Director
Stephen Farr
Chief Financial Officer/Executive Vice President/Treasurer/Secretary
Michael Smith
Executive Vice President/General Counsel/Secretary
Shawnte Mitchell
Executive Vice President
Gail Farfel
Executive Vice President
Bradley Galer
Executive Vice President
Ashish Sagrolikar
Independent Director
Louis Bock
Independent Director
James Breitmeyer
Independent Director
Caroline Loewy
Independent Director
Erle Mast
Independent Director
Mary Stutts
Independent Director
Renee Tannenbaum
Independent Director
Denelle Waynick
Independent Director
Mark Wiggins
暂无数据
ZGNX 简况
Zogenix, Inc.是一家制药公司,致力于开发与商业化满足罕见与其他中枢神经系统(CNS)疾病患者特殊临床需求的CNS疗法。该公司的主要业务领域是癫痫和精神分裂症。该公司的主导候选产品ZX008是一种低剂量氟苯丙胺。该公司还从事Relday的开发,Relday是一种用于治疗成年人和13岁及以上青少年的精神分裂症和双相性精神障碍的长效利培酮注射制剂。该公司还从事制造Sumavel DosePro(舒马曲坦注射剂),一种销售给Endo Ventures Bermuda Limited和Endo Ventures Limited的无针给药系统。该公司的DosePro技术是一种为预填充单剂量液体药物皮下无针自行注射设计的给药系统。

微牛提供Zogenix, Inc.(NASDAQ-ZGNX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ZGNX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ZGNX股票基本功能。